

Fiona H Blackhall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1780681/publications.pdf>

Version: 2024-02-01

264
papers

27,073
citations

15880

67
h-index

7234

158
g-index

268
all docs

268
docs citations

268
times ranked

32205
citing authors

#	ARTICLE	IF	CITATIONS
1	Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. <i>NAR Cancer</i> , 2022, 4, .	1.6	4
2	A local human V β 1 T cell population is associated with survival in nonsmall-cell lung cancer. <i>Nature Cancer</i> , 2022, 3, 696-709.	5.7	39
3	Abstract 6238: Profiling of the circulating cell-free DNA methylome for detection and subtyping of small cell lung cancers. <i>Cancer Research</i> , 2022, 82, 6238-6238.	0.4	1
4	Abstract 2975: RAS precision medicine transatlantic partnership: Exploration of RAS and NF1 co-mutations in NSCLC. <i>Cancer Research</i> , 2022, 82, 2975-2975.	0.4	0
5	Real-World Data on Pembrolizumab for Pretreated Non-Small-Cell Lung Cancer: Clinical Outcome and Relevance of the Lung Immune Prognostic Index. <i>Targeted Oncology</i> , 2022, 17, 453-465.	1.7	4
6	Aprepitant for Cough in Lung Cancer. A Randomized Placebo-controlled Trial and Mechanistic Insights. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 737-745.	2.5	30
7	Mechanisms of Resistance to KRASG12C Inhibitors. <i>Cancers</i> , 2021, 13, 151.	1.7	81
8	Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial. <i>Lung Cancer</i> , 2021, 153, 165-170.	0.9	11
9	Global Physiology and Pathophysiology of Cough. <i>Chest</i> , 2021, 160, 1413-1423.	0.4	5
10	EPAC-lung: European pooled analysis of the prognostic value of circulating tumour cells in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1653-1665.	1.3	8
11	Validation of ROS1 by immunohistochemistry against fluorescent in situ hybridisation on cytology and small biopsy samples in a large teaching hospital. <i>Cytopathology</i> , 2021, 32, 621-630.	0.4	4
12	Abstract 2874: Understanding small cell lung cancer metastasis using circulating tumor cell (CTC)-derived tumor explant (CDX) models. , 2021, , .		0
13	Using DNA sequencing data to quantify T cell fraction and therapy response. <i>Nature</i> , 2021, 597, 555-560.	13.7	36
14	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	0.5	108
15	Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists. <i>British Journal of Cancer</i> , 2021, 125, 1210-1216.	2.9	10
16	Soluble guanylate cyclase signalling mediates etoposide resistance in progressing small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6652.	5.8	14
17	TIAM1-RAC1 promote small-cell lung cancer cell survival through antagonizing Nur77-induced BCL2 conformational change. <i>Cell Reports</i> , 2021, 37, 109979.	2.9	13
18	Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 216-230.	0.5	49

#	ARTICLE	IF	CITATIONS
19	Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer. <i>Oncologist</i> , 2020, 25, 55-63.	1.9	123
20	Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants. <i>Lung Cancer</i> , 2020, 150, 216-220.	0.9	7
21	The Rare YAP1 Subtype of SCLC Revisited in a Biobank of 39 Circulating Tumor Cell Patient Derived Explant Models: A Brief Report. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1836-1843.	0.5	45
22	Liquid Biopsy in Small Cell Lung Cancer – A Route to Improved Clinical Care?. <i>Cells</i> , 2020, 9, 2586.	1.8	3
23	Reliability and prognostic value of radiomic features are highly dependent on choice of feature extraction platform. <i>European Radiology</i> , 2020, 30, 6241-6250.	2.3	115
24	Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue. <i>Cell Reports</i> , 2020, 31, 107550.	2.9	51
25	Managing Chronic Cough as a Symptom in Children and Management Algorithms. <i>Chest</i> , 2020, 158, 303-329.	0.4	63
26	A cross sectional study to determine the prevalence of cough and its impact in patients with lung cancer: a patient unmet need. <i>BMC Cancer</i> , 2020, 20, 9.	1.1	17
27	A biobank of small cell lung cancer CDX models elucidates inter- and intratumoral phenotypic heterogeneity. <i>Nature Cancer</i> , 2020, 1, 437-451.	5.7	103
28	<i>Ex vivo</i> culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics. <i>British Journal of Pharmacology</i> , 2019, 176, 436-450.	2.7	34
29	Developing and testing a web-based intervention to encourage early help-seeking in people with symptoms associated with lung cancer. <i>British Journal of Health Psychology</i> , 2019, 24, 31-65.	1.9	10
30	Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. <i>Nature Medicine</i> , 2019, 25, 1534-1539.	15.2	146
31	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.3	24
32	Direct Ras G12C inhibitors: crossing the rubicon. <i>British Journal of Cancer</i> , 2019, 121, 197-198.	2.9	37
33	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40
34	KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition. <i>EBioMedicine</i> , 2019, 41, 711-716.	2.7	142
35	Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 63-71.	0.5	37
36	Cough in Patients With Lung Cancer. <i>Chest</i> , 2019, 155, 103-113.	0.4	34

#	ARTICLE	IF	CITATIONS
37	Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, e185335.	3.4	46
38	Is heterogeneity in stage 3 non-small cell lung cancer obscuring the potential benefits of dose-escalated concurrent chemo-radiotherapy in clinical trials?. <i>Lung Cancer</i> , 2018, 118, 139-147.	0.9	10
39	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
40	Chronic Cough Related to Acute Viral Bronchiolitis in Children. <i>Chest</i> , 2018, 154, 378-382.	0.4	7
41	Cell Death, Inflammation, Tumor Burden, and Proliferation Blood Biomarkers Predict Lung Cancer Radiotherapy Response and Correlate With Tumor Volume and Proliferation Imaging. <i>Clinical Lung Cancer</i> , 2018, 19, 239-248.e7.	1.1	16
42	A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. <i>Journal of Thoracic Disease</i> , 2018, 10, 3909-3921.	0.6	35
43	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	0.8	308
44	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018, 3, e000408.	2.0	4
45	Will liquid biopsies improve outcomes for patients with small-cell lung cancer?. <i>Lancet Oncology</i> , 2018, 19, e470-e481.	5.1	63
46	The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5153-5164.	3.2	126
47	Treatment of Interstitial Lung Disease Associated Cough. <i>Chest</i> , 2018, 154, 904-917.	0.4	50
48	Investigation of myositis and scleroderma specific autoantibodies in patients with lung cancer. <i>Arthritis Research and Therapy</i> , 2018, 20, 176.	1.6	7
49	Classification of Cough as a Symptom in Adults and Management Algorithms. <i>Chest</i> , 2018, 153, 196-209.	0.4	281
50	Symptomatic Treatment of Cough Among Adult Patients With Lung Cancer. <i>Chest</i> , 2017, 151, 861-874.	0.4	50
51	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	0.8	470
52	Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors. <i>Immunity</i> , 2017, 46, 577-586.	6.6	323
53	Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1844.	3.8	281
54	Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. <i>Nature</i> , 2017, 545, 446-451.	13.7	1,287

#	ARTICLE	IF	CITATIONS
55	Tracking the Evolution of Non-“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2109-2121.	13.9	1,786
56	Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-“Small-Cell Lung Cancer: ERCC1 Trial (ET). <i>Journal of Clinical Oncology</i> , 2017, 35, 402-411.	0.8	54
57	Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. <i>Lancet Oncology</i> , The, 2017, 18, 1116-1125.	5.1	415
58	Etiologies of Chronic Cough in Pediatric Cohorts. <i>Chest</i> , 2017, 152, 607-617.	0.4	63
59	P2.03b-031 Impact of PD-L1 Status on Clinical Response in SELECT-1: Selumetinib + Docetaxel in KRASm Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, S952-S953.	0.5	2
60	Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. <i>Patient</i> , 2017, 10, 593-603.	1.1	9
61	Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. <i>Cell</i> , 2017, 171, 1259-1271.e11.	13.5	968
62	Is it time to convert the frequency of radiotherapy in small-cell lung cancer? “ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e556.	5.1	4
63	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. <i>British Journal of Cancer</i> , 2017, 117, 938-946.	2.9	18
64	Cough in Ambulatory Immunocompromised Adults. <i>Chest</i> , 2017, 152, 1038-1042.	0.4	5
65	Pharmacologic and Nonpharmacologic Treatment for Acute Cough Associated With the Common Cold. <i>Chest</i> , 2017, 152, 1021-1037.	0.4	59
66	Molecular analysis of single circulating tumour cells following long-term storage of clinical samples. <i>Molecular Oncology</i> , 2017, 11, 1687-1697.	2.1	12
67	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1588-1594.	0.5	21
68	Randomised Phase 2 study of maintenance linsitinib (OSI-906) in combination with erlotinib compared with placebo plus erlotinib after platinum-based chemotherapy in patients with advanced non-small cell lung cancer. <i>British Journal of Cancer</i> , 2017, 117, 757-766.	2.9	24
69	Targeting DNA damage in SCLC. <i>Lung Cancer</i> , 2017, 114, 12-22.	0.9	36
70	Assessment of Breathlessness in Lung Cancer: Psychometric Properties of the Dyspnea-12 Questionnaire. <i>Journal of Pain and Symptom Management</i> , 2017, 53, 208-215.	0.6	31
71	Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer. <i>Nature Medicine</i> , 2017, 23, 114-119.	15.2	260
72	Cough in the Athlete. <i>Chest</i> , 2017, 151, 441-454.	0.4	25

#	ARTICLE	IF	CITATIONS
73	Spotlight on circulating tumour cells. <i>Translational Lung Cancer Research</i> , 2017, 6, 396-396.	1.3	0
74	Circulating tumor cells and CDX models as a tool for preclinical drug development. <i>Translational Lung Cancer Research</i> , 2017, 6, 397-408.	1.3	68
75	The clinical utility of circulating tumour cells in patients with small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2017, 6, 409-417.	1.3	28
76	Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. <i>ESMO Open</i> , 2017, 2, e000219.	2.0	87
77	Molecular resistance mechanisms of ALK inhibitors and implications for therapeutic management of ALK-rearranged lung cancer patients. <i>Translational Cancer Research</i> , 2017, 6, S239-S245.	0.4	2
78	Protocol for the CONVERT trial—Concurrent ONce-daily VErus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status. <i>BMJ Open</i> , 2016, 6, e009849.	0.8	37
79	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i>-Positive Non-“Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	0.8	216
80	Inhibition of PI3K/BMX Cell Survival Pathway Sensitizes to BH3 Mimetics in SCLC. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1248-1260.	1.9	30
81	Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?. <i>Drugs</i> , 2016, 76, 831-840.	4.9	13
82	Chronic Cough Due to Gastroesophageal Reflux in Adults. <i>Chest</i> , 2016, 150, 1341-1360.	0.4	158
83	Identification and Targeting of Long-Term Tumor-Propagating Cells in Small Cell Lung Cancer. <i>Cell Reports</i> , 2016, 16, 644-656.	2.9	73
84	Occupational and Environmental Contributions to Chronic Cough in Adults. <i>Chest</i> , 2016, 150, 894-907.	0.4	26
85	Selumetinib in the treatment of non-small-cell lung cancer. <i>Future Oncology</i> , 2016, 12, 2545-2560.	1.1	23
86	Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1793-1797.	0.5	80
87	Vasculogenic mimicry in small cell lung cancer. <i>Nature Communications</i> , 2016, 7, 13322.	5.8	206
88	Current Status of Immunotherapy for Non-Small-Cell Lung Cancer. <i>Tumori</i> , 2016, 102, 337-351.	0.6	6
89	Treatment of Unexplained Chronic Cough. <i>Chest</i> , 2016, 149, 27-44.	0.4	263
90	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	0.5	156

#	ARTICLE	IF	CITATIONS
91	Genetic profiling of tumours using both circulating free DNA and circulating tumour cells isolated from the same preserved whole blood sample. <i>Molecular Oncology</i> , 2016, 10, 566-574.	2.1	74
92	Development of a circulating miRNA assay to monitor tumor burden: From mouse to man. <i>Molecular Oncology</i> , 2016, 10, 282-291.	2.1	18
93	Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumour cells in patients with small cell lung cancer. <i>Analyst</i> , 2016, 141, 669-678.	1.7	95
94	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. <i>Clinical Cancer Research</i> , 2016, 22, 366-373.	3.2	20
95	Somatic Cough Syndrome (Previously Referred to as Psychogenic Cough) and Tic Cough (Previously) Tj ETQq1 1 0.784314 rgBT /Over	0.4	76
96	Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, ii15.	0.6	2
97	Outcomes of Octogenarian (≥80 YO) Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): a Single Institution Experience from the Christie Hospital. <i>Annals of Oncology</i> , 2015, 26, i29.	0.6	0
98	Tools for Assessing Outcomes in Studies of Chronic Cough. <i>Chest</i> , 2015, 147, 804-814.	0.4	99
99	Diagnostic Mutation Profiling and Validation of Non-Small-Cell Lung Cancer Small Biopsy Samples using a High Throughput Platform. <i>Journal of Thoracic Oncology</i> , 2015, 10, 784-792.	0.5	16
100	Assessment of Intervention Fidelity and Recommendations for Researchers Conducting Studies on the Diagnosis and Treatment of Chronic Cough in the Adult. <i>Chest</i> , 2015, 148, 32-54.	0.4	46
101	Discovery and Validation of Predictive Biomarkers of Survival for Non-small Cell Lung Cancer Patients Undergoing Radical Radiotherapy: Two Proteins With Predictive Value. <i>EBioMedicine</i> , 2015, 2, 841-850.	2.7	24
102	1: Circulating tumour cells from small cell lung cancer patients are tumourigenic. <i>Lung Cancer</i> , 2015, 87, S1.	0.9	4
103	Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 497-504.	0.6	56
104	113: Do standardised uptake values from PET-CT scans predict EGFR status of lung tumours?. <i>Lung Cancer</i> , 2015, 87, S41.	0.9	0
105	144: A single centre's experience of toxicity, compliance and survival in patients with stage III locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemo-radiotherapy (CCTRT). <i>Lung Cancer</i> , 2015, 87, S52-S53.	0.9	0
106	167: Thoracic radiotherapy in extensive stage small cell lung cancer. <i>Lung Cancer</i> , 2015, 87, S61.	0.9	0
107	Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064). <i>European Journal of Cancer</i> , 2015, 51, 1511-1528.	1.3	27
108	Management of the respiratory distress symptom cluster in lung cancer: a randomised controlled feasibility trial. <i>Supportive Care in Cancer</i> , 2015, 23, 3373-3384.	1.0	70

#	ARTICLE	IF	CITATIONS
109	Strategies in ALK Rearranged NSCLC Patients. , 2015, , 147-156.		0
110	Abstract IA05: Circulating tumor cells in lung cancer: Biomarkers, biology, and mouse models to study drug resistance. , 2015, , .		0
111	Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study. PLoS Biology, 2014, 12, e1001906.	2.6	185
112	Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 2014, 32, 2780-2787.	0.8	163
113	First-Line Crizotinib versus Chemotherapy in <i>ALK</i> -Positive Lung Cancer. New England Journal of Medicine, 2014, 371, 2167-2177.	13.9	2,808
114	264 Vasculogenic mimicry in small cell lung cancer. European Journal of Cancer, 2014, 50, 88.	1.3	0
115	Evaluation and validation of a robust single cell RNA-amplification protocol through transcriptional profiling of enriched lung cancer initiating cells. BMC Genomics, 2014, 15, 1129.	1.2	19
116	Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study. Journal of Thoracic Oncology, 2014, 9, 991-997.	0.5	46
117	Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment of Patients with Non-Small-Cell Lung Cancer: A Randomized Open-Label Phase II Study. Journal of Thoracic Oncology, 2014, 9, 1704-1708.	0.5	29
118	Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non-Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study. Journal of Thoracic Oncology, 2014, 9, 1154-1161.	0.5	19
119	Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients with ALK-Positive Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 1625-1633.	0.5	74
120	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. Journal of Thoracic Oncology, 2014, 9, 1675-1684.	0.5	31
121	31 The use of pemetrexed in advanced non-small cell lung cancer. Lung Cancer, 2014, 83, S12.	0.9	0
122	How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?. Lung Cancer, 2014, 83, 117-125.	0.9	35
123	Early reduction in tumour [18F]fluorothymidine (FLT) uptake in patients with non-small cell lung cancer (NSCLC) treated with radiotherapy alone. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 682-693.	3.3	39
124	22 Mutation profiling of non-small cell lung cancer small biopsy samples using mass spectrometry and the SequenomLungCarta Panel. Lung Cancer, 2014, 83, S9.	0.9	0
125	Molecular analysis of circulating tumour cells—biology and biomarkers. Nature Reviews Clinical Oncology, 2014, 11, 129-144.	12.5	535
126	Modafinil for the Treatment of Fatigue in Lung Cancer: Results of a Placebo-Controlled, Double-Blind, Randomized Trial. Journal of Clinical Oncology, 2014, 32, 1882-1888.	0.8	106

#	ARTICLE	IF	CITATIONS
127	Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 926-937.	3.2	256
128	59: CTCs and cfDNA, will they be useful for early detection of cancer?. <i>European Journal of Cancer</i> , 2014, 50, S15.	1.3	0
129	Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing. <i>British Journal of Cancer</i> , 2014, 111, 413-420.	2.9	41
130	Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer. <i>Nature Medicine</i> , 2014, 20, 897-903.	15.2	608
131	152 The impact of IMRT on the treatment of patients with N3M0 lung cancer at The Christie. <i>Lung Cancer</i> , 2014, 83, S56.	0.9	0
132	185 CONVERT – a successful international collaboration between the UK NCRI, Groupe Français de Pneumo-Cancérologie, Spanish Lung Cancer Group, EORTC and NCI Canada. <i>Lung Cancer</i> , 2014, 83, S69.	0.9	0
133	100 The –CLIC–cough in lung cancer study: Co-morbidities are key predictors of cough. <i>Lung Cancer</i> , 2014, 83, S37.	0.9	2
134	First-Line Crizotinib Vs Pemetrexed + Cisplatin/Carboplatin in Asian Patients with Advanced Alk+ Nsclc in Profile 1014. <i>Annals of Oncology</i> , 2014, 25, v2.	0.6	3
135	Anatomy and Neurophysiology of Cough. <i>Chest</i> , 2014, 146, 1633-1648.	0.4	227
136	Abstract 3060: Circulating tumor cells from small cell lung cancer patients are tumorigenic. , 2014, , .		0
137	Availability of EGFR mutation status at first oncology consultation for advanced non-squamous non-small cell lung cancer patients. A pilot experience from the Christie. <i>Lung Cancer</i> , 2013, 82, 510-511.	0.9	3
138	Integrated molecular portrait of non-small cell lung cancers. <i>BMC Medical Genomics</i> , 2013, 6, 53.	0.7	51
139	Clinical Utility of Circulating Tumour Cell Detection in Non-Small-Cell Lung Cancer. <i>Current Treatment Options in Oncology</i> , 2013, 14, 610-622.	1.3	20
140	The impact on the multidisciplinary team of molecular profiling for personalized therapy in non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 101-103.	0.9	12
141	Guideline on the requirements of external quality assessment programs in molecular pathology. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 27-37.	1.4	70
142	103 Do treatment decisions made at lung cancer multi-disciplinary team meetings (MDTs) reflect the actual treatment given in practice?. <i>Lung Cancer</i> , 2013, 79, S36.	0.9	4
143	184 Toxicities and compliance to treatment in locally advanced non-small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (cCRT) at the Christie NHS Foundation Trust. <i>Lung Cancer</i> , 2013, 79, S63-S64.	0.9	0
144	48 Radical management of inoperable stage III non-small cell lung cancer (NSCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN) – an analysis of patient eligibility and justification for treatment. <i>Lung Cancer</i> , 2013, 79, S16.	0.9	0

#	ARTICLE	IF	CITATIONS
145	The Manchester Cough in Lung Cancer Scale: The Development and Preliminary Validation of a New Assessment Tool. <i>Journal of Pain and Symptom Management</i> , 2013, 45, 179-190.	0.6	18
146	Treatment and detection of ALK-rearranged NSCLC. <i>Lung Cancer</i> , 2013, 81, 145-154.	0.9	30
147	Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 2385-2394.	13.9	3,181
148	Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients. <i>British Journal of Cancer</i> , 2013, 108, 1704-1711.	2.9	32
149	P58...The Characterisation and Subjective Assessment of Cough in Lung Cancer and Mesothelioma: The CLAIM-Study. <i>Thorax</i> , 2013, 68, A101.1-A101.	2.7	1
150	P59...The Characterisation of Cough in Lung Cancer. <i>Thorax</i> , 2013, 68, A101.2-A102.	2.7	0
151	Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers. <i>Translational Lung Cancer Research</i> , 2013, 2, 382-97.	1.3	29
152	Treatment of Limited-Stage Disease in Older Patients: The Role of Thoracic Radiotherapy and Prophylactic Cranial Irradiation. , 2013, , 223-232.		0
153	Abstract 1468: Circulating tumor cells (CTCs) and circulating tumor microemboli (CTM) from patients with small cell lung cancer (SCLC) show heterogeneity in epithelial to mesenchymal transition (EMT) phenotype and evidence of vasculogenic mimicry (VM).. , 2013, , .		0
154	Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-“Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3337-3344.	0.8	247
155	Variant Ciz1 is a circulating biomarker for early-stage lung cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E3128-35.	3.3	49
156	Understanding cough and its management in lung cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 153-162.	0.5	24
157	Analysis of Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Using Epithelial Marker-Dependent and -Independent Approaches. <i>Journal of Thoracic Oncology</i> , 2012, 7, 306-315.	0.5	411
158	Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients With Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 525-532.	0.8	755
159	Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. <i>Lung Cancer</i> , 2012, 76, 19-25.	0.9	153
160	89 Management of stage III non-small-cell lung cancer (NSCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN): an analysis of current practice. <i>Lung Cancer</i> , 2012, 75, S30.	0.9	0
161	161 Acute toxicity of prophylactic cranial irradiation (PCI) in extensive stage small cell lung cancer (ES-SCLC): A prospective audit from a UK radiotherapy centre. <i>Lung Cancer</i> , 2012, 75, S53.	0.9	0
162	178 The National Lung Cancer Audit (NLCA) does not accurately record chemotherapy administration for patients with small cell lung cancer (SCLC) in the Greater Manchester and Cheshire Cancer Network (GMCCN). <i>Lung Cancer</i> , 2012, 75, S58-S59.	0.9	0

#	ARTICLE	IF	CITATIONS
163	182 Do circulating tumour cell (CTC) counts correlate with tumour volume in limited disease small cell lung cancer (LD-SCLC)? An exploratory clinical study with survival outcomes. <i>Lung Cancer</i> , 2012, 75, S60.	0.9	1
164	199 Pulmonary vein circulating tumour cells from patients undergoing curative resection of non-small cell lung cancer. <i>Lung Cancer</i> , 2012, 75, S65.	0.9	0
165	Considerations in developing and delivering a non-pharmacological intervention for symptom management in lung cancer: the views of health care professionals. <i>Supportive Care in Cancer</i> , 2012, 20, 2565-2574.	1.0	20
166	Considerations in Developing and Delivering a Nonpharmacological Intervention for Symptom Management in Lung Cancer: The Views of Patients and Informal Caregivers. <i>Journal of Pain and Symptom Management</i> , 2012, 44, 831-842.	0.6	41
167	International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: MONET1. <i>Journal of Clinical Oncology</i> , 2012, 30, 2829-2836.	0.8	179
168	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. <i>British Journal of Cancer</i> , 2012, 106, 508-516.	2.9	233
169	Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. <i>Cancer Treatment Reviews</i> , 2012, 38, 626-640.	3.4	76
170	Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer â€“ Evidence from a phase II trial. <i>Lung Cancer</i> , 2012, 76, 72-77.	0.9	39
171	Biomarkers for small cell lung cancer: Neuroendocrine, epithelial and circulating tumour cells. <i>Lung Cancer</i> , 2012, 76, 263-268.	0.9	39
172	Applying Bestâ€“Worst scaling methodology to establish delivery preferences of a symptom supportive care intervention in patients with lung cancer. <i>Lung Cancer</i> , 2012, 77, 199-204.	0.9	25
173	Liquid Chromatographyâ€“Mass Spectrometry Calibration Transfer and Metabolomics Data Fusion. <i>Analytical Chemistry</i> , 2012, 84, 9848-9857.	3.2	33
174	Extrapulmonary small cell carcinoma: a clinicopathological study with identification of potential diagnostic mimics. <i>Histopathology</i> , 2012, 61, 454-464.	1.6	25
175	Biology and clinical relevance of circulating tumour cells. <i>Journal of Thoracic Disease</i> , 2012, 4, 453-5.	0.6	3
176	Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Nonâ€“Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 1556-1563.	0.8	788
177	Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Nonâ€“Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 1067-1074.	0.8	268
178	9072 POSTER Pemetrexed (Pern) Maintenance Therapy in Elderly Patients (Pts) With Good Performance Status (PS) â€“ Analysis of PARAMOUNT Phase III Study of Pern Versus Placebo in Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC). <i>European Journal of Cancer</i> , 2011, 47, S613.	1.3	1
179	Optimization of Circulating Biomarkers of Obatoclox-Induced Cell Death in Patients with Small Cell Lung Cancer. <i>Neoplasia</i> , 2011, 13, 339-347.	2.3	19
180	9084 POSTER A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC). <i>European Journal of Cancer</i> , 2011, 47, S617.	1.3	9

#	ARTICLE	IF	CITATIONS
181	A qualitative exploration of a respiratory distress symptom cluster in lung cancer: Cough, breathlessness and fatigue. <i>Lung Cancer</i> , 2011, 71, 94-102.	0.9	86
182	Outcomes of small-cell lung cancer patients treated with second-line chemotherapy: A multi-institutional retrospective analysis. <i>Lung Cancer</i> , 2011, 72, 378-383.	0.9	56
183	Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group. <i>Lung Cancer</i> , 2011, 73, 338-344.	0.9	4
184	Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. <i>Lung Cancer</i> , 2011, 74, 75-9.	0.9	17
185	Is Serum or Plasma More Appropriate for Intersubject Comparisons in Metabolomic Studies? An Assessment in Patients with Small-Cell Lung Cancer. <i>Analytical Chemistry</i> , 2011, 83, 6689-6697.	3.2	119
186	Circulating Tumor Cells as a Window on Metastasis Biology in Lung Cancer. <i>American Journal of Pathology</i> , 2011, 178, 989-996.	1.9	386
187	10IN NEW TOOLS IN THE MOLECULAR DIAGNOSTIC OF LUNG CANCER. <i>Lung Cancer</i> , 2011, 71, S7.	0.9	0
188	Treatment of limited small cell lung cancer: an old or new challenge?. <i>Current Opinion in Oncology</i> , 2011, 23, 158-162.	1.1	9
189	Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?. <i>Thorax</i> , 2011, 66, 273-275.	2.7	7
190	Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4442-4451.	0.8	227
191	Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy. <i>Annals of Oncology</i> , 2011, 22, 1507-1519.	0.6	117
192	Hypoxic human cancer cells are sensitized to BH-3 mimetic-induced apoptosis via downregulation of the Bcl-2 protein Mcl-1. <i>Journal of Clinical Investigation</i> , 2011, 121, 1075-1087.	3.9	46
193	A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1285-1288.	0.5	34
194	Improving Survival with Thoracic Radiotherapy in Patients with Small Cell Lung Cancer. The CONVERT and the REST Trials. <i>Clinical Oncology</i> , 2010, 22, 547-549.	0.6	8
195	Clinical expert guidelines for the management of cough in lung cancer: report of a UK task group on cough. <i>Cough</i> , 2010, 6, 9.	2.7	44
196	Circulating Tumor Cells, Enumeration and Beyond. <i>Cancers</i> , 2010, 2, 1236-1250.	1.7	42
197	Principles of Cancer Treatment. , 2010, , 1-9.		0
198	Circulating tumour cells: their utility in cancer management and predicting outcomes. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 351-365.	1.4	224

#	ARTICLE	IF	CITATIONS
199	Review: Targeted therapies in small cell lung cancer: a review. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 25-37.	1.4	42
200	Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 1527-1533.	0.8	209
201	The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. <i>Annals of Oncology</i> , 2010, 21, 2023-2028.	0.6	91
202	The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials Unit. <i>Annals of Oncology</i> , 2010, 21, 232-237.	0.6	80
203	Gefitinib for the treatment of non-small-cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2010, 11, 1343-1357.	0.9	20
204	Omitting elective nodal irradiation (ENI) during thoracic irradiation in limited-stage small cell lung cancer (LS-SCLC) Patterns of failure from a phase II trial. <i>Lung Cancer</i> , 2010, 67, S10.	0.9	1
205	Evaluating the safety of using G-CSF prophylaxis during concurrent thoracic chemo-radiotherapy (CRT) in patients with limited-disease small-cell lung cancer (LD-SCLC): Evidence from a phase II trial. <i>Lung Cancer</i> , 2010, 67, S10-S11.	0.9	0
206	RADAR Radiation damage and resistance in patients with lung cancer. <i>Lung Cancer</i> , 2010, 67, S32-S33.	0.9	0
207	Pharmacogenetics in Lung Cancer. , 2010, , 87-99.		0
208	Antivascular agents for non-small-cell lung cancer: current status and future directions. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1667-1686.	1.9	7
209	The Influence of Sex in Non-Small Cell Lung Cancer. <i>Onkologie</i> , 2009, 32, 547-548.	1.1	3
210	Radiotherapy in Extensive-disease Small Cell Lung Cancer. A Survey of Current UK Practice. <i>Clinical Oncology</i> , 2009, 21, 78.	0.6	4
211	Radiotherapy for small-cell lung cancer—Where are we heading?. <i>Lung Cancer</i> , 2009, 63, 307-314.	0.9	40
212	<i>UGT1A1</i> *28 genotype predicts gastrointestinal toxicity in patients treated with intermediate-dose irinotecan. <i>Pharmacogenomics</i> , 2009, 10, 733-739.	0.6	34
213	Feasibility and toxicity report from a phase II study of accelerated twice-daily (BDRT) versus high dose once-daily thoracic radiotherapy (ODRT) with concurrent chemotherapy for limited-stage small cell lung cancer (LS-SCLC). <i>Lung Cancer</i> , 2009, 63, S11-S12.	0.9	0
214	Detection of EGFR and KRAS mutations in circulating free DNA in patients with operable non small cell lung cancer (NSCLC). <i>Lung Cancer</i> , 2009, 63, S20.	0.9	0
215	Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy. <i>American Journal of Pathology</i> , 2009, 175, 808-816.	1.9	223
216	EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?. <i>Targeted Oncology</i> , 2008, 3, 173-186.	1.7	3

#	ARTICLE	IF	CITATIONS
217	Update on targeted therapies for small cell carcinoma of the lung. <i>Targeted Oncology</i> , 2008, 3, 205-215.	1.7	3
218	Isolation and Extraction of Circulating Tumor DNA from Patients with Small Cell Lung Cancer. <i>Annals of the New York Academy of Sciences</i> , 2008, 1137, 98-107.	1.8	90
219	Phase III randomised trial of doxorubicin-based chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer. <i>British Journal of Cancer</i> , 2008, 99, 442-447.	2.9	43
220	Management of Unresectable Stage III Non-Small-Cell Lung Cancer with Combined-Modality Therapy: A Review of the Current Literature and Recommendations for Treatment. <i>Clinical Lung Cancer</i> , 2008, 9, 92-101.	1.1	24
221	Prophylactic cranial irradiation (PCI) in extensive disease (ED) small cell lung cancer (SCLC): an audit of practice. <i>Lung Cancer</i> , 2008, 60, S4.	0.9	1
222	Tarceva in relapsed non-small cell lung cancer: experience from Northwest England. <i>Lung Cancer</i> , 2008, 60, S25-S26.	0.9	0
223	Optimisation of circulating biomarkers of cell death for routine clinical use. <i>Annals of Oncology</i> , 2008, 19, 990-995.	0.6	68
224	Targeting Blood Vessels for the Treatment of Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 392-403.	0.8	10
225	Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor. <i>Journal of Endocrinology</i> , 2008, 198, 499-509.	1.2	71
226	X-linked inhibitor of apoptosis protein as a therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1459-1471.	1.5	44
227	Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 3265-3275.	0.9	11
228	Three-Gene Prognostic Classifier for Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 5562-5569.	0.8	226
229	B2-06: A pragmatic, randomised study to compare the hospitalisation rates of two platinum-based outpatient regimens (Gemcitabine/Cisplatin vs. Gemcitabine/Carboplatin) in non-small cell lung cancer (NSCLC) - UK Swiss collaboration. <i>Journal of Thoracic Oncology</i> , 2007, 2, S338.	0.5	2
230	Small cell lung cancer and targeted therapies. <i>Current Opinion in Oncology</i> , 2007, 19, 103-108.	1.1	27
231	Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. <i>Cancer Treatment Reviews</i> , 2007, 33, 203-212.	3.4	44
232	35 CONVERT-A multicentre randomised controlled NCRN trial comparing accelerated twice-daily and high dose once-daily thoracic radiotherapy in good performance status (PS), limited small-cell lung cancer (LD SCLC) treated concurrently with cisplatin and etoposide. <i>Lung Cancer</i> , 2007, 57, S10.	0.9	0
233	Small Cell Lung Cancer (SCLC); any progress?. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 398-399.	2.2	0
234	Management of cancer from an unknown primary. <i>Expert Opinion on Pharmacotherapy</i> , 2007, 8, 445-455.	0.9	9

#	ARTICLE	IF	CITATIONS
235	DNA Methylation in Circulating Tumour DNA as a Biomarker for Cancer. <i>Biomarker Insights</i> , 2007, 2, 117727190700200.	1.0	26
236	E11-03: Controversy in small cell lung cancer: targeted therapy. <i>Journal of Thoracic Oncology</i> , 2007, 2, S251-S253.	0.5	0
237	Where next for gefitinib in patients with lung cancer?. <i>Lancet Oncology</i> , The, 2006, 7, 499-507.	5.1	116
238	427 POSTER Preclinical development of xiapuradamib therapy for lung cancer. <i>European Journal of Cancer</i> , Supplement, 2006, 4, 130.	2.2	0
239	Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2006, 53, 165-170.	0.9	1
240	Pharmacogenetics in the Management of Breast Cancer – Prospects for Individualised Treatment. <i>Familial Cancer</i> , 2006, 5, 151-157.	0.9	8
241	K-ras Mutations in Non-Small-Cell Lung Carcinoma: A Review. <i>Clinical Lung Cancer</i> , 2006, 8, 30-38.	1.1	212
242	The Morphogenic Properties of Oligomeric Endostatin Are Dependent on Cell Surface Heparan Sulfate. <i>Journal of Biological Chemistry</i> , 2006, 281, 14813-14822.	1.6	7
243	Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. <i>Current Opinion in Oncology</i> , 2005, 17, 135-139.	1.1	20
244	Sequential Platinum-Based Chemotherapy-Thoracic Radiotherapy in Early Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5051s-5056s.	3.2	9
245	O-126 Expression profiling of matrix metalloproteinases (MMPs) and inhibitors reveals a novel prognostic role for MMP-19 in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2005, 49, S43-S44.	0.9	1
246	Platinum-based chemotherapy with thoracic radiotherapy in stage III good performance status non-small cell lung cancer patients. <i>European Journal of Cancer</i> , Supplement, 2005, 3, 41-50.	2.2	0
247	P-625 Quantitative PCR validation of putative non-small cell lungcancer (NSCLC) prognostic marker genes derived from multiple published microarray databases and reports. <i>Lung Cancer</i> , 2005, 49, S283.	0.9	0
248	Erlotinib in non-small cell lung cancer: a review. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 995-1002.	0.9	11
249	Perspectives on novel therapies for bronchial carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 1157-1167.	0.9	7
250	Interstitial Lung Disease in Lung Cancer. <i>Drug Safety</i> , 2005, 28, 103-113.	1.4	60
251	Improving Survival and Reducing Toxicity with Chemotherapy in Advanced Non-Small Cell Lung Cancer. <i>Treatments in Respiratory Medicine</i> , 2005, 4, 71-84.	1.4	35
252	Distribution and Clinical Significance of Heparan Sulfate Proteoglycans in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 5178-5186.	3.2	135

#	ARTICLE	IF	CITATIONS
253	Skp2 Gene Copy Number Aberrations Are Common in Non-Small Cell Lung Carcinoma, and Its Overexpression in Tumors with ras Mutation Is a Poor Prognostic Marker. <i>Clinical Cancer Research</i> , 2004, 10, 1984-1991.	3.2	79
254	Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. <i>Oncogene</i> , 2004, 23, 6316-6324.	2.6	31
255	Angiogenesis inhibitors in the treatment of small cell and non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 1121-1141.	0.9	15
256	Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. <i>Lung Cancer</i> , 2004, 46, 197-204.	0.9	43
257	Stability and Heterogeneity of Expression Profiles in Lung Cancer Specimens Harvested Following Surgical Resection. <i>Neoplasia</i> , 2004, 6, 761-767.	2.3	43
258	Chemotherapy for advanced lung cancer. <i>European Journal of Cancer</i> , 2004, 40, 2345-2348.	1.3	12
259	Genetic alterations of lung adenocarcinoma in relation to smoking and ethnicity. <i>Lung Cancer</i> , 2003, 41, 91-99.	0.9	19
260	Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates. <i>Biochemical Journal</i> , 2003, 375, 131-139.	1.7	39
261	Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. <i>Clinical Cancer Research</i> , 2003, 9, 2241-7.	3.2	90
262	Semen cryopreservation, utilisation and reproductive outcome in men treated for Hodgkin's disease. <i>British Journal of Cancer</i> , 2002, 87, 381-384.	2.9	75
263	A phase II trial of bryostatin 1 in patients with non-Hodgkin's lymphoma. <i>British Journal of Cancer</i> , 2001, 84, 465-469.	2.9	61
264	Heparan sulfate proteoglycans and cancer. <i>British Journal of Cancer</i> , 2001, 85, 1094-1098.	2.9	152